35981-66-9 Usage
Description
(4-(Bromomethyl)phenyl)(cyclopropyl)methanone is a ketone compound with the molecular formula C11H11BrO. It features a cyclopropyl group attached to a phenyl group with a bromomethyl substituent, and contains a carbonyl group (C=O). This chemical is utilized in organic synthesis and pharmaceutical research, with its properties and reactivity offering potential for various applications within the field of chemistry.
Used in Organic Synthesis:
(4-(Bromomethyl)phenyl)(cyclopropyl)methanone is used as an intermediate in organic synthesis for the creation of various complex organic molecules. Its unique structure allows for the formation of new chemical bonds and the synthesis of diverse compounds.
Used in Pharmaceutical Research:
In the pharmaceutical industry, (4-(Bromomethyl)phenyl)(cyclopropyl)methanone is used as a starting material or building block in the development of new drugs. Its reactivity and functional groups can be leveraged to create pharmaceutically active compounds with potential therapeutic applications.
It is crucial to handle (4-(Bromomethyl)phenyl)(cyclopropyl)methanone with care and follow safety protocols, as it may pose hazards if not properly managed.
Check Digit Verification of cas no
The CAS Registry Mumber 35981-66-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,5,9,8 and 1 respectively; the second part has 2 digits, 6 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 35981-66:
(7*3)+(6*5)+(5*9)+(4*8)+(3*1)+(2*6)+(1*6)=149
149 % 10 = 9
So 35981-66-9 is a valid CAS Registry Number.
35981-66-9Relevant articles and documents
AZETIDINE COMPOUNDS AS GRP119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS
-
Paragraph 0258, (2018/09/12)
The present disclosure relates to azetidine compounds. The azetidine compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The present disclosure furthermore relates to the use of azetidine compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.
